Full-Time

Technical Illustrator

Updated on 3/7/2025

Biorender

Biorender

201-500 employees

Online platform for scientific illustrations

Entry, Junior

Remote in Canada

Category
Graphic & Motion Design
UI/UX & Design
Required Skills
Adobe Illustrator
Requirements
  • Background in technical illustration (BA from an accredited illustration program and/or professional technical illustration experience)
  • Demonstrates a strong sense of visual design + composition skills (composing scientific diagrams and infographics is a plus)
  • Strong draftsmanship, line work, sense of perspective, color, and composition
  • Strong portfolio of technical illustration work
  • Ability to execute production of high-quality vector images quickly and efficiently using illustration tools (like Adobe Illustrator)
  • Ability to quickly research and understand a variety of subjects and topics and translate into clean, clear, didactic 2D images
  • Team player with a strong interest to take on collaborative team projects
  • Strong communication skills
Responsibilities
  • Research and create clean, accurate, 2D vector-based graphics across all domains of life sciences, with a special focus on graphics of technical objects/hardware scientists use in their research
  • Manage and support multiple high-impact scientific creative projects in collaboration with other scientific illustrators and designers, as part of BioRender’s objective-driven cycles (set up meetings, keep track of project scope, follow through to ensure timely deliverable completions, etc.)
  • Communicate with scientists and users on illustration needs, accuracy, and requested services
  • Contribute to team reviews on illustration/design productions, to ensure team-wide quality and standards of visual content
  • Collaborate with other teams (engineers, sales and marketing, product design, UI/UX etc.) to deliver a consistent and cohesive body of work
  • Assess and identify opportunity areas for scientific content library expansion and growth as our platform and library grows in global reach
Desired Qualifications
  • Life science / Education background is preferred but not required

BioRender provides an online platform for creating scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform's user-friendly interface enables clients, including academic researchers, pharmaceutical companies, and educational institutions, to create figures for research papers, presentations, and educational materials with minimal effort. BioRender operates on a subscription model, offering various plans to suit different user needs, including enterprise solutions for larger organizations. The company's goal is to simplify the process of creating high-quality scientific illustrations, making it an essential resource for effective scientific communication.

Company Size

201-500

Company Stage

Series A

Total Funding

$16.7M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for digital communication boosts need for scientific visualization tools.
  • Growing interest in graphical abstracts enhances research visibility and accessibility.
  • Open-access publishing trend increases demand for high-quality, appealing figures.

What critics are saying

  • AI-driven design tools may reduce demand for BioRender's platform.
  • Increased competition from cheaper visualization platforms could erode market share.
  • Potential IP disputes over pre-drawn icons could lead to legal challenges.

What makes Biorender unique

  • BioRender offers a vast library of customizable icons and templates for scientists.
  • The platform provides a user-friendly interface for creating professional scientific figures.
  • BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

3%

2 year growth

5%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.